Novo Nordisk Q3 Adj. EPS DKK 5.79, Down 12% YoY; Sales DKK 79.2B vs DKK 75.0B YoY
Share
Why It Matters
Novo Nordisk made more money than last year, but earned less per share. Sales grew, yet profits per share fell, so watch if this trend continues.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.